Aggregate, published by WILEY, is a premier open-access journal established in 2020, dedicated to advancing the fields of Chemistry, Materials Chemistry, Materials Science, and Molecular Biology. Based in the United States, this rapidly rising journal (Q1 in various categories as of 2023) has quickly made its mark as a valuable resource, evidenced by its impressive Scopus rankings—ranking #6 in Chemistry (miscellaneous) and #13 in Materials Science (miscellaneous) among others—place it firmly in the top percentiles of these disciplines. With an emphasis on rigorous peer-reviewed research, Aggregate provides an essential platform for researchers to disseminate groundbreaking findings and innovative methodologies that propel the scientific community forward. As an open-access journal, it ensures that cutting-edge research is accessible to a global audience, thereby enriching the dialogue among professionals, researchers, and students alike. Explore the latest advancements and contribute to the vibrant discourse in these critical areas of science by publishing with Aggregate.

BIOMACROMOLECULES, published by the American Chemical Society, stands as a premier journal in the fields of bioengineering, biomaterials, materials chemistry, and polymers and plastics. With a commendable impact factor that places it in the Q1 category across these disciplines, it is recognized for its influential research contributions and is ranked strongly within its scopes—16th in Polymers and Plastics and 26th in Biomaterials according to Scopus. Since its inception in 2000 and continuing through 2024, the journal has been pivotal in disseminating significant findings and technological advancements that propel the field forward. Although it does not currently have an open access option, the journal offers invaluable insights that are essential for researchers, professionals, and students engaged in the cutting-edge exploration of macromolecules and their diverse applications. With its address located at 1155 16th St, NW, Washington, DC 20036, BIOMACROMOLECULES is not just a repository of knowledge but also a vital platform for fostering collaboration and innovation within the scientific community.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

European Journal of Medicinal Chemistry Reports, published by ELSEVIER, is a vital platform dedicated to advancing the field of medicinal chemistry through open access communication of high-quality research. With an impact factor reflecting its growing influence, this journal has rapidly established a reputation for scholarly excellence since its launch in 2021. It serves as a converging point for innovative studies and reviews that span the disciplines of chemistry and molecular medicine, reflected in its Q2 and Q3 quartile rankings in relevant categories for 2023. Situated in France, the journal is accessible globally, ensuring that researchers, professionals, and students can easily engage with significant findings and methodologies in medicinal chemistry. The open access model facilitates the dissemination of knowledge, bridging gaps between laboratory research and practical applications in drug development. By fostering collaboration and highlighting emerging trends, the European Journal of Medicinal Chemistry Reports plays a crucial role in shaping the future of therapeutic innovations.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

ACS Bio & Med Chem Au, published by the esteemed American Chemical Society, stands at the forefront of interdisciplinary research within the realms of biochemistry, drug discovery, pharmaceutical sciences, and molecular biology. With an impressive Impact Factor indicative of its rigorous academic standards and significant contributions to the field, this open-access journal is committed to disseminating high-quality research that drives innovation and advancements in biosciences and medicinal chemistry. Since its inception in 2021, the journal has rapidly earned recognition, achieving a commendable Q1 ranking in multiple categories, including Biochemistry, Drug Discovery, and Pharmaceutical Science, while also making strides in Molecular Biology. Researchers, professionals, and students alike can explore pioneering studies that bridge gaps between laboratory research and clinical applications, fostering collaborative efforts towards novel therapeutic strategies. With a focus on enhancing accessibility and engagement within the scientific community, ACS Bio & Med Chem Au is poised to impact the future of biomedical research significantly.

VIEW is a prestigious journal published by WILEY that focuses on the rapidly evolving fields of Biomaterials and Biomedical Engineering. Since its inception in 2020, VIEW has established itself as an open-access platform dedicated to disseminating high-quality research and innovation within these disciplines. With an impressive impact factor that places it in the Q1 category of both Biomaterials and Biomedical Engineering, VIEW ranks among the top journals in its field, boasting a 91st percentile ranking in Biomedical Engineering and an 85th percentile ranking in Materials Science. Researchers, professionals, and students are encouraged to utilize this invaluable resource, as it provides a comprehensive view of current advancements and future trends in biomaterial science and engineering. Positioned in the United Kingdom, VIEW operates as a vital scholarly communication link, fostering collaboration and knowledge sharing within an ever-growing global community.

ACS Chemical Biology is a premier journal published by the American Chemical Society, dedicated to advancing the understanding of the chemical underpinnings of biological systems. With an ISSN of 1554-8929 and a distinguished track record since its inception in 2006, this journal provides a vital platform for the dissemination of high-quality research in the realms of biochemistry and molecular medicine, achieving a prestigious Q1 ranking in these categories as of 2023. In an era where interdisciplinary approaches are crucial, ACS Chemical Biology fosters collaboration among chemists and biologists, reflecting a steadfast commitment to exploring the chemical processes that govern life. Although it does not operate under an open-access model, the journal maintains a rigorous peer-review process, ensuring the publication of influential studies that shape the future of chemical biology. With an increasing impact factor and a focus on innovative research, ACS Chemical Biology remains an authoritative resource for researchers, professionals, and students eager to engage with cutting-edge findings in this dynamic field.

Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.